Screener / SEC EDGAR /CIK 0001651308 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

BeOne Medicines Ltd. ONC

Compare with peers Embed
FY2025 at a glance

Sales up 40.2%, free cash flow up to $941.7M

XBRL, from each 10-K
RevenueStatements
$5.3B from $3.8B in FY2024
FY2016FY2025
Net incomeStatements
$286.9M from -$644.8M in FY2024
FY2016FY2025
Free cash flowStatements
$941.7M from -$633.3M in FY2024
FY2016FY2025
EPS (diluted)Statements
$0.19 from $-0.47 in FY2024
FY2016FY2025
Operating marginStatements
8.4% from -14.9% in FY2024
FY2016FY2025
Total debtStatements
$845.4M from $1.9B in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (41)
EPS (ttm)
0.60
Sales (ttm)
6.6B
Net income (ttm)
915.6M
Sales growth
+40.2%
EPS growth
-
Sales Q/Q
+33.8%
Free cash flow
1.4B
Gross margin
89.4%
Oper. margin
17.8%
Net margin
13.9%
FCF margin
21.9%
ROA
9.3%
R&D / sales
40.2%
Dividend
-
Debt/Eq
0.15
Curr. ratio
3.55
Cash
5.8B
Op. cash flow (ttm)
1.6B
EBITDA
588.8M
EBITDA margin
11.0%
Net debt
-4.9B
Quick ratio
3.28
Interest cover
7.68
ROIC
4.6%
FCF after stock pay
430.9M
Debt / FCF (years)
0.92
Oper. margin low 5y
-126.4%
Tax rate
31.2%
Stock pay / sales
9.6%
Shares out.
1.5B
Shares Y/Y
+7.8%
Book / share
3.92
Cash / share
3.89
Sales / share
4.45
Asset turnover
0.67
Days sales out.
59
Sales 3Y CAGR
+55.7%
Sales 5Y CAGR
+76.9%
Employees
12,000
Sales / employee
551K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 5.3B +157.6% a year Net income 286.9M
FY2016 revenue 1.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-19-000018 FY2016 net income -119.2M · NetIncomeLoss, 0001651308-19-000018 1.1M FY2016 FY2017 revenue 238.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-20-000020 FY2017 net income -93.1M · NetIncomeLoss, 0001651308-20-000020 238.4M FY2017 FY2018 revenue 198.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-21-000039 FY2018 net income -673.8M · NetIncomeLoss, 0001651308-21-000039 198.2M FY2018 FY2019 revenue 428.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-21-000039 FY2019 net income -948.6M · NetIncomeLoss, 0001651308-22-000032 428.2M FY2019 FY2020 revenue 308.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-23-000036 FY2020 net income -1.6B · NetIncomeLoss, 0001651308-23-000036 308.9M FY2020 FY2021 revenue 1.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-24-000014 FY2021 net income -1.5B · NetIncomeLoss, 0001651308-24-000014 1.2B FY2021 FY2022 revenue 1.4B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001651308-25-000031 FY2022 net income -2.0B · NetIncomeLoss, 0001651308-25-000031 1.4B FY2022 FY2023 revenue 2.5B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-011946 FY2023 net income -881.7M · NetIncomeLoss, 0001628280-26-011946 2.5B FY2023 FY2024 revenue 3.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-011946 FY2024 net income -644.8M · NetIncomeLoss, 0001628280-26-011946 3.8B FY2024 FY2025 revenue 5.3B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-011946 FY2025 net income 286.9M · NetIncomeLoss, 0001628280-26-011946 5.3B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +15.7% a year FY2019 $1.23 to FY2025 $2.96, 6 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.19$2.96$0.64
Dec 31, 2024 -$0.47$2.43-$0.46
Dec 31, 2023 -$0.65$2.61-$1.27
Dec 31, 2022 -$1.49$3.27-$1.36
Dec 31, 2021 -$1.21$5.08-$1.29
Dec 31, 2020 -$1.50$3.57-$1.29
Dec 31, 2019 -$1.22$1.23-$1.08
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $6.2B
  • − All liabilities $3.8B
  • = Net current asset value $2.4B
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $4.4B
  • − Other intangible assets $62.7M
  • = Tangible book value $4.3B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ONC against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+40.2%19th of 155 · median +10.5%
Net margin
-4.1%15.3%
13.9%45th of 154 · median 6.8%
Return on equity
-5.2%18.5%
15.7%44th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
21.9%26th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.1512th of 108 · median 0.69
ONC and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ONC BeOne Medicines Ltd.$6.6B +40.2%89.4%13.9%15.7%21.9%0.15
EW Edwards Lifesciences$6.7B +11.5%78.0%15.3%9.4%21.3%0.06
EHC Encompass Health Corp$6.3B +10.5%-10.2%24.0%7.2%0.97
STE Steris$6.2B +8.7%44.6%13.4%11.4%15.2%0.26
OGN Organon & Co.$6.1B -2.9%53.1%3.5%17.9%11.1%7.23
INCY Incyte$6.0B +21.2%92.7%6.7%7.1%--
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $5.3B of sales to $286.9M of profit FY2025

  • Product revenue, net $5.3B
  • Other revenue $61.0M
Revenue to Gross profit: $4.7BRevenue to Cost of revenue: $668.5MGross profit to Operating profit: $447.1MGross profit to Operating expenses: $4.2BOperating profit to Net profit: $286.9MOperating profit to Tax & other: $160.2MOperating expenses to R&D: $2.1BOperating expenses to SG&A: $2.1B Revenue: $5.3B REVENUE $5.3B +40% Y/Y Gross profit: $4.7B · 87% margin GROSS PROFIT $4.7B 87% margin · +45% Y/Y Cost of revenue: $668.5M · 13% of revenue COST OF REVENUE $668.5M 13% of revenue Operating profit: $447.1M · 8% margin OPERATING PROFIT $447.1M 8% margin Operating expenses: $4.2B · 79% of revenue OPERATING EXPENSES $4.2B 79% of revenue Net profit: $286.9M · 5% margin NET PROFIT $286.9M 5% margin Tax & other: $160.2M · 3% of revenue TAX & OTHER $160.2M 3% of revenue R&D: $2.1B · 40% of revenue R&D $2.1B 40% of revenue SG&A: $2.1B · 39% of revenue SG&A $2.1B 39% of revenue

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 6.6% FY2020: -42.0% net income ÷ equity
Net margin 5.4% FY2020: -526.1% profit per $ of sales: 286.9M ÷ 5.3B
Asset turnover 0.65× FY2020: 0.06× sales per $ of assets: 5.3B ÷ 8.2B
Leverage 1.88× FY2020: 1.45× assets per $ of equity: 8.2B ÷ 4.4B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    13.9% vs 6.8%
  • Gross margin up over 4 years
    86.0% → 87.5%
  • Return on equity above 15%
    15.7%
  • A profit in 1 of 10 years
Net margin, FY2016 to FY2025: -11141.8% to 5.4%

Balance sheet

  • Interest covered more than 5 times
    Operating income is 7.7× interest expense
  • Debt smaller than equity
    Debt / equity 0.15 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 3.55
  • More cash than debt
    Net cash $4.9B
Debt / equity at each year end, FY2016 to FY2025: 0.05 to 0.19

Cash and shareholders

  • Free cash flow positive in 1 of 10 years
    $941.7M last year
  • Share count up over 5 years
    +35.9%
  • Cash from operations above net income
    $1.1B vs $286.9M
Free cash flow, FY2016 to FY2025: -113.0M to 941.7M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$- of principal due

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ONC's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue5.3B
FY2016: 1.1MFY2017: 238.4MFY2018: 198.2MFY2019: 428.2MFY2020: 308.9MFY2021: 1.2BFY2022: 1.4BFY2023: 2.5BFY2024: 3.8BFY2025: 5.3B FY2017FY2019FY2021FY2023FY2025
Net income286.9M
FY2016: -119.2MFY2017: -93.1MFY2018: -673.8MFY2019: -948.6MFY2020: -1.6BFY2021: -1.5BFY2022: -2.0BFY2023: -881.7MFY2024: -644.8MFY2025: 286.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow941.7M
FY2016: -113.0MFY2017: -33.6MFY2018: -618.0MFY2019: -839.9MFY2020: -1.4BFY2021: -1.6BFY2022: -1.8BFY2023: -1.7BFY2024: -633.3MFY2025: 941.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay430.9M
FY2016: -123.6MFY2017: -76.5MFY2018: -705.1MFY2019: -974.0MFY2020: -1.6BFY2021: -1.8BFY2022: -2.1BFY2023: -2.1BFY2024: -1.1BFY2025: 430.9M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)0.19
FY2016: -0.30FY2017: -0.17FY2018: -0.93FY2019: -1.22FY2020: -1.50FY2021: -1.21FY2022: -1.49FY2023: -0.65FY2024: -0.47FY2025: 0.19 FY2017FY2019FY2021FY2023FY2025
Diluted shares1.5B
FY2016: -FY2017: -FY2018: -FY2019: 780.7MFY2020: 1.1BFY2021: 1.2BFY2022: 1.3BFY2023: 1.4BFY2024: 1.4BFY2025: 1.5B FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Product revenue, net 5.3B98.9% +39.8%
Other revenue 61.0M1.1% +98.6%

10-K 0001628280-26-011946, segment and revenue notes (XBRL).

Revenue by region

year to Dec 31, 2025
RevenueSharevs year before
U.S. - total revenue 2.9B53.9% +47.1%
China- total revenue 1.7B31.4% +19.0%
Europe- total revenue 611.4M11.4% +68.6%
Rest of world- total revenue 171.8M3.2% +118%

10-K 0001628280-26-011946, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1.1M238.4M198.2M428.2M308.9M1.2B1.4B2.5B3.8B5.3B
Cost of revenue05.0M28.7M71.2M70.7M164.9M286.5M---
Gross profit-----1.0B1.1B2.1B3.2B4.7B
R&D98.0M269.0M679.0M927.3M1.3B1.5B1.6B1.8B2.0B2.1B
SG&A20.1M62.6M195.4M388.2M600.2M990.1M1.3B1.5B1.8B2.1B
Operating income-117.1M-98.5M-705.8M-959.9M-1.7B-1.4B-1.8B-1.2B-568.2M447.1M
Interest expense826K1.3M13.1M15.2M18.3M29.3M21.7M4.4M21.8M58.2M
Pretax income-119.2M-91.1M-689.8M-943.6M-1.6B-1.4B-2.0B-825.8M-533.0M416.9M
Income tax54K2.2M-15.8M7.0M10.4M19.2M42.8M55.9M111.8M129.9M
Net income-119.2M-93.1M-673.8M-948.6M-1.6B-1.5B-2.0B-881.7M-644.8M286.9M
EPS (diluted)-0.30-0.17-0.93-1.22-1.50-1.21-1.49-0.65-0.470.19
Diluted shares---780.7M1.1B1.2B1.3B1.4B1.4B1.5B
Depreciation & amortization1.9M4.8M10.4M18.6M31.8M46.5M66.3M87.7M171.8M141.7M
EBITDA-115.2M-93.7M-695.4M-941.3M-1.6B-1.4B-1.7B-1.1B-396.4M588.8M
Gross margin-----86.0%79.8%84.5%84.4%87.5%
Operating margin-10940.2%-41.3%-356.1%-224.2%-536.7%-122.3%-126.4%-49.1%-14.9%8.4%
Net margin-11141.8%-39.1%-339.9%-221.5%-526.1%-123.9%-141.5%-35.9%-16.9%5.4%
Revenue growth-87.9%+22179%-16.8%+116%-27.9%+281%+20.4%+73.7%+55.0%+40.2%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-89.5M12.8M-547.7M-750.3M-1.3B-1.3B-1.5B-1.2B-140.6M1.1B
Capital spending23.5M46.4M70.3M89.6M117.5M262.9M325.4M561.9M492.7M185.8M
Free cash flow-113.0M-33.6M-618.0M-839.9M-1.4B-1.6B-1.8B-1.7B-633.3M941.7M
Stock-based pay (added back)10.6M42.9M87.1M134.2M183.5M240.7M303.2M367.6M441.6M510.9M
Free cash flow after stock pay-123.6M-76.5M-705.1M-974.0M-1.6B-1.8B-2.1B-2.1B-1.1B430.9M
Debt raised--42.3M67.5M433.9M-----
Debt repaid008.7M32.8M132.1M0013.7M28.0M35.7M
Investing cash flow-221.8M-356.3M-637.6M554.2M-3.2B640.7M1.1B60.0M-548.4M-276.2M
Financing cash flow380.9M490.4M1.7B85.7M5.2B3.6B-19.0M416.5M193.4M1.1B

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)10.6M42.9M87.1M134.2M183.5M240.7M303.2M367.6M441.6M510.9M
Stock-based pay / revenue993.0%18.0%44.0%31.3%59.4%20.5%21.4%15.0%11.6%9.6%
Operating lease cost---14.0M18.3M22.5M25.9M26.0M26.6M24.9M
Operating lease cash paid---12.4M17.6M20.0M28.1M28.0M56.0M24.0M
Right-of-use assets-12.5M45.1M82.5M90.6M117.4M110.0M95.2M139.3M148.2M
Operating lease liabilities--27.4M36.6M43.3M65.0M58.6M44.2M61.9M73.6M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.